Please login to the form below

Not currently logged in
Email:
Password:

CAR therapies

This page shows the latest CAR therapies news and features for those working in and with pharma, biotech and healthcare.

NICE wants to stop saying ‘no’ – but needs pharma’s co-operation

NICE wants to stop saying ‘no’ – but needs pharma’s co-operation

industry. Recent examples of this include rapid pricing deals on the two CAR-T therapies, Novartis’ Kymriah and Gilead’s Yescarta. ... This includes cell and gene therapies such as Novartis’ late-stage candidate Zolgensma, which the company has

Latest news

  • NICE partially clears Darzalex combo in blood cancer NICE partially clears Darzalex combo in blood cancer

    When used in combination with Velcade and corticosteroid medication dexamethasone, those taking Darzalex achieved an extended progression free survival of 18 months compared to existing therapies. ... Myeloma is an increasingly dynamic and competitive

  • CMS proposes coverage scheme for CAR-T therapies CMS proposes coverage scheme for CAR-T therapies

    Proposal says it would improve access to CAR-Ts. New proposals in the US would lay out a route for approved CAR-T therapies to be covered by the federal Medicare ... will collect data on patients and compare the outcomes to the results seen in

  • How to pay for very high cost, curative drugs? ICER and NICE put their heads together How to pay for very high cost, curative drugs? ICER and NICE put their heads together

    Like many other cell and gene therapies, it could represent a cure for the disease – but comes with a huge upfront cost that healthcare systems aren’t currently set up to ... It is now working closely with NHS England (which negotiates directly on

  • EMA sees approval numbers rise in 2018 EMA sees approval numbers rise in 2018

    From these, 21 were orphan medicines (exactly 50%) and three were advanced therapy medicinal products – Novartis’ Kymriah and Gilead/Kite’s Yescarta CAR-T therapies, plus Spark’s Luxturna, co-marketed

  • BMS and Celgene announce $74bn merger BMS and Celgene announce $74bn merger

    Two of Celgene’s most promising candidates are in BCMA-targeting CAR-T therapies for multiple myeloma – one with Bluebird, bb2121, and another with Juno, JCAR017.

More from news
Approximately 1 fully matching, plus 55 partially matching documents found.

Latest Intelligence

  • Cell and gene therapy Cell and gene therapy

    Manufacturing of CAR-T cell therapies is a highly sophisticated, circular process that is individualised for each patient, beginning with the patient’s cells and ending with infusion in that same ... But, obviously, these prices will have to decrease

  • 2019: CRISPR and therapeutic gene editing comes of age 2019: CRISPR and therapeutic gene editing comes of age

    TALEN is now being deployed most widely in chimeric antigen receptor T cell (CAR-T) therapies, which generally involve harvesting T cells from patients, modifying them to attack tumour cells by ... and that therapies based on the approach must be

  • Cutting through the noise: CRISPR Cutting through the noise: CRISPR

    Scientists can then examine the effect of this change, uncovering potential disease targets for therapies. ... It’s very difficult to systemically deliver a CRISPR therapeutic selectively to the right place, especially when there are easier ways of

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    1. Zolgensma – the $4m per patient gene therapy. The first CAR-T cell therapies, Novartis’ Kymriah and Gilead/Kite’s Yescarta, were launched in Europe in 2018, while Spark’s gene ... oral therapies such as Tyk inhibitors from Bristol-Myers Squibb

  • China’s clinical trial shake-up China’s clinical trial shake-up

    Once seen as a manufacturer of generics rather than a developer of innovative drugs, China is now involved in half of all enrolling cancer trials of CAR-T cell therapies.

More from intelligence
Approximately 0 fully matching, plus 20 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hanson Zandi

Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...

Latest intelligence

Where next in Alzheimer’s disease R&D?
How past failures and emerging biology are reshaping drug development...
Brain scan
Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...

Infographics